LICENCE AGREEMENT betweenLicence Agreement • August 16th, 2004 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • England
SENETEK plc, a company incorporated under the Companies Acts (Registered No. 01759068) and having its registered office at 3 Howard Road, Eaton Socon, Cambridgeshire PE19 3ET, and its principal place of business at 620 Airpark Road, Napa, California 94558 (“Senetek”);
AGREEMENTCollaboration Agreement • August 16th, 2004 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
This Agreement (the “Agreement”) is made and entered into as of May 4, 2004, by and between Senetek PLC, an English corporation with its corporate headquarters located at 620 Airpark Road, Napa, California 94558 (“Senetek”), and Valeant Pharmaceuticals International, a Delaware corporation with its corporate headquarters located at 3300 Hyland Avenue, Costa Mesa, California 92626 (“Valeant”).
Consulting AgreementConsulting Agreement • August 16th, 2004 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • California
This CONSULTING AGREEMENT is made this First day of June, 2004, by and between Senetek PLC, a company organized under the laws of England with its principal place of business at 620 Airpark Road, Napa, California 94558 (“Senetek” and, together with its subsidiaries, the “Company”) and Andreas Tobler, an individual residing at 14 Stack House, Cundy Street Flats, Cundy Street, London SW1W 9JS, United Kingdom (“Consultant”). This Agreement shall be effective as of May 1, 2004.
AMENDMENT #5License Agreement • August 16th, 2004 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
The Agreement between the Research Foundation for Mental Hygiene, Inc. and Senetek PLC executed July 21, 1994 is hereby amended for the purpose of extending the license on the three original licensed cell lines.
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • August 16th, 2004 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
This Amendment (the “Amendment”) is made and entered into as of April , 2004 to the License Agreement made and entered into as of August 1, 2003, as amended as of December 1, 2003 (the “Agreement”), by and between Senetek PLC, an English corporation with its corporate headquarters located at 620 Airpark Road, Napa, California 94558 (“Senetek”), and Valeant Pharmaceuticals International (formerly known as ICN Pharmaceuticals, Inc), a Delaware corporation with its corporate headquarters located at 3300 Hyland Avenue, Costa Mesa, California 92626 (“Licensee”). Capitalized terms used herein and not otherwise defined are used with the meanings ascribed to them in the Agreement.
